Aurélie Ledreux (USA) analyzed AD-related biomarkers [tau, p-tau, amyloid-beta (Aβ) peptides Aβ 1–40, Aβ1-42, and neurofilament-light] and neuroinflammatory biomarkers in NDEVs obtained from plasma of individuals with DS and correlated them with cognitive measures to investigate if they would predict disease trajectory and age of dementia onset. This evidence concerns the gene MAPT and Dravet syndrome.